PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $870,729 | -46.8% | 28,381 | -30.5% | 0.00% | – |
| Q2 2023 | $1,635,336 | -49.3% | 40,812 | -48.4% | 0.00% | -100.0% |
| Q1 2023 | $3,227,948 | +7.6% | 79,097 | +1.8% | 0.00% | 0.0% |
| Q4 2022 | $2,998,607 | -29.4% | 77,664 | -2.7% | 0.00% | 0.0% |
| Q3 2022 | $4,245,000 | -13.2% | 79,810 | -4.9% | 0.00% | -50.0% |
| Q2 2022 | $4,891,000 | -19.5% | 83,907 | +5.3% | 0.00% | 0.0% |
| Q1 2022 | $6,079,000 | +21.8% | 79,648 | -3.9% | 0.00% | +100.0% |
| Q4 2021 | $4,990,000 | -78.2% | 82,919 | -79.7% | 0.00% | -80.0% |
| Q3 2021 | $22,888,000 | -52.5% | 408,711 | -48.5% | 0.01% | -54.5% |
| Q2 2021 | $48,153,000 | -56.2% | 793,554 | -49.4% | 0.01% | -56.0% |
| Q1 2021 | $109,872,000 | +31.3% | 1,567,574 | +12.1% | 0.02% | +25.0% |
| Q4 2020 | $83,655,000 | +71.0% | 1,397,974 | +71.8% | 0.02% | +42.9% |
| Q3 2020 | $48,914,000 | +80.9% | 813,600 | +57.9% | 0.01% | +75.0% |
| Q2 2020 | $27,032,000 | +429.5% | 515,188 | +238.4% | 0.01% | +300.0% |
| Q1 2020 | $5,105,000 | -14.9% | 152,254 | +14.9% | 0.00% | 0.0% |
| Q4 2019 | $6,002,000 | +6.6% | 132,483 | -10.4% | 0.00% | 0.0% |
| Q3 2019 | $5,632,000 | -18.1% | 147,941 | -6.5% | 0.00% | 0.0% |
| Q2 2019 | $6,880,000 | +37.2% | 158,210 | +20.1% | 0.00% | +100.0% |
| Q1 2019 | $5,015,000 | +52.1% | 131,772 | +71.9% | 0.00% | 0.0% |
| Q4 2018 | $3,297,000 | -4.6% | 76,639 | +9.0% | 0.00% | 0.0% |
| Q3 2018 | $3,457,000 | +55.2% | 70,334 | +1.2% | 0.00% | 0.0% |
| Q2 2018 | $2,228,000 | -56.8% | 69,517 | -66.6% | 0.00% | -50.0% |
| Q1 2018 | $5,161,000 | -19.4% | 207,973 | +15.8% | 0.00% | 0.0% |
| Q4 2017 | $6,407,000 | +40.4% | 179,659 | +47.8% | 0.00% | +100.0% |
| Q3 2017 | $4,565,000 | +15.8% | 121,585 | +47.1% | 0.00% | 0.0% |
| Q2 2017 | $3,942,000 | -1.4% | 82,645 | -5.7% | 0.00% | 0.0% |
| Q1 2017 | $3,997,000 | +146.3% | 87,658 | +74.4% | 0.00% | 0.0% |
| Q4 2016 | $1,623,000 | +21.8% | 50,251 | +29.0% | 0.00% | – |
| Q3 2016 | $1,333,000 | -88.9% | 38,952 | -89.0% | 0.00% | -100.0% |
| Q2 2016 | $11,983,000 | -60.2% | 355,250 | -37.5% | 0.01% | -58.3% |
| Q1 2016 | $30,099,000 | +21.2% | 568,131 | +75.7% | 0.01% | +20.0% |
| Q4 2015 | $24,835,000 | +1322.4% | 323,412 | +661.2% | 0.01% | +900.0% |
| Q3 2015 | $1,746,000 | -95.1% | 42,488 | -91.5% | 0.00% | -92.9% |
| Q2 2015 | $35,485,000 | -70.1% | 501,758 | -62.4% | 0.01% | -39.1% |
| Q1 2015 | $118,564,000 | +191.8% | 1,334,412 | +191.2% | 0.02% | +43.8% |
| Q4 2014 | $40,632,000 | +3.0% | 458,287 | +12.6% | 0.02% | -5.9% |
| Q3 2014 | $39,452,000 | +6.1% | 407,064 | +0.6% | 0.02% | +13.3% |
| Q2 2014 | $37,183,000 | +223.6% | 404,785 | +146.6% | 0.02% | +200.0% |
| Q1 2014 | $11,490,000 | +58.3% | 164,169 | +30.1% | 0.01% | +66.7% |
| Q4 2013 | $7,257,000 | +26.9% | 126,207 | +6.1% | 0.00% | 0.0% |
| Q3 2013 | $5,717,000 | +85.0% | 118,917 | +11.5% | 0.00% | +50.0% |
| Q2 2013 | $3,091,000 | – | 106,610 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |